Tumor is an Oxidative Stress Factor in Ovarian Cancer Patients

Trifănescu, Oana; Gruia, Ion; Galeş, Laurenţia; Trifănescu, Raluca; Anghel, Rodica

doi:10.21614/chirurgia.113.5.687

Cited by 6 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, recent studies have indicated that increased level of antioxidants are also prevalent in cancer cells to detoxify ROS and at the same time sustain enhanced mitogenic signaling to promote tumourigenesis, resistance to therapy and apoptosis [240]. Increased ROS production has been reported for ovarian tumours [241]. This may relate to genetic instability, DNA damage repair deficiency, enhanced aggressiveness and the chemoresistant phenotype of the disease as discussed previously.…”

Section: Role Of Magmas Inhibitor In Ovarian Cancer Treatmentmentioning

confidence: 89%

Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods

Ahmed

Kadife²,

Raza

et al. 2020

Cells

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) constitutes 90% of ovarian cancers (OC) and is the eighth most common cause of cancer-related death in women. The cancer histologically and genetically is very complex having a high degree of tumour heterogeneity. The pathogenic variability in OC causes significant impediments in effectively treating patients, resulting in a dismal prognosis. Disease progression is predominantly influenced by the peritoneal tumour microenvironment rather than properties of the tumor and is the major contributor to prognosis. Standard treatment of OC patients consists of debulking surgery, followed by chemotherapy, which in most cases end in recurrent chemoresistant disease. This review discusses the different origins of high-grade serous ovarian cancer (HGSOC), the major sub-type of EOC. Tumour heterogeneity, genetic/epigenetic changes, and cancer stem cells (CSC) in facilitating HGSOC progression and their contribution in the circumvention of therapy treatments are included. Several new treatment strategies are discussed including our preliminary proof of concept study describing the role of mitochondria-associated granulocyte macrophage colony-stimulating factor signaling protein (Magmas) in HGSOC and its unique potential role in chemotherapy-resistant disease. of 35have been observed in OC patients but not in patients with benign and borderline tumours, and this hypomethylation correlates with advanced-stage disease and poor prognosis [48,49]. A genome-wide methylation profiling of blood cells from healthy controls and age-matched untreated OC patients identified CpG methylation of 2714 cancer-related genes, of which 56% were hypomethylated [50]. Ovarian Cancer Stem CellsCellular heterogeneity associated with genetic and epigenetic changes in tumours are linked with the initiation and expansion of CSCs, a population of cells within the tumour, which initiate tumour growth through self-renewal and differentiation processes [51,52]. These cells are more adaptive to the changing tumour microenvironment and tend to be more resistant to treatment. CSCs are highly plastic and a few numbers of isolated CSCs have been shown to be responsible for tumorgenesis and are more chemotherapy and radiation resistant due to their dormant state and a high expression of drug efflux pumps [53,54]. As a result, CSCs are able to adapt to different tumour microenvironments and survive due to their efficient DNA repair mechanisms and their capacity to evade host immune surveillance [55][56][57]. These inherent properties of CSCs suggest an active role in tumour relapse and emphasize the need to develop effective targeted therapies to improve clinical outcomes in patients [51][52][53][54][55][56][57].Stem cells have been identified in ovaries and fallopian tubes [58,59]. These cells express proteins including aldehyde dehydrogenase family 1 A2 (ALDH1A2), homeobox protein NANOG, LIM homeobox protein 9 (LHX9) and frizzled-related protein 1 (SRFP1) and have been observed in OSE, CIC and fimbria [2,[58][59][60][61][62]. In a...

show abstract

Section: Role Of Magmas Inhibitor In Ovarian Cancer Treatmentmentioning

confidence: 89%

Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods

Ahmed

Kadife²,

Raza

et al. 2020

Cells

View full text Add to dashboard Cite

show abstract

“…Oxidative stress and ROS are involved in the development of various diseases including cancers. [ 51,52 ] However, within the tumor microenvironment, cancer cells have high basal oxidative stress with an induced antioxidant system, and therefore can evade ROS‐induced cell death. [ 53,54 ] Our EAC mouse model showed significantly increased MDA levels with decreased TAC.…”

Section: Discussionmentioning

confidence: 99%

Antitumor activity of sitagliptin and vitamin B12 on Ehrlich ascites carcinoma solid tumor in mice

Salah

Salama

Mahgoub

et al. 2020

J Biochem & Molecular Tox

View full text Add to dashboard Cite

This study was carried out to investigate the potential effects of vitamin B12 and sitagliptin, and their possible synergistic effect with doxorubicin (DOX) on the Ehrlich solid tumor model. B12, sitagliptin, and their combination with DOX were administered to tumor‐bearing mice for 21 days. Treatment with B12, sitagliptin, as well as their combinations with DOX caused a significant inhibition of tumor growth and increased the survival time. Malondialdehyde levels and the relative expression of tumor necrosis factor‐α and nuclear factor kappa B were significantly decreased, whereas the total antioxidant capacity was significantly increased in all treated groups, except the DOX‐treated one, when compared with the positive control group. Moreover, increased apoptosis was also observed by increased cleaved caspase‐3 immunostaining and histopathological examination. In conclusion, the antitumor activity of B12 and sitagliptin could be attributed to their ability to induce apoptosis and suppress oxidative stress and inflammation.

show abstract

“…Moreover, in another study the mean values of serum MDA and ceruloplasmin were significantly higher in patients with macroscopic residual tumour after surgery compared to patients without residual tumours, the study demonstrating that the tumour was an oxidative stress inducer [27].…”

Section: Resultsmentioning

confidence: 88%

Malondialdehyde as a Prognostic Marker in Patients with Ovarian Adenocarcinoma

Trifănescu¹,

Gruia²,

Galeş³

et al. 2019

Rev. Chim.

Self Cite

View full text Add to dashboard Cite

Oxidative stress is defined as the imbalance between reactive oxygen species and cellular antioxidative mechanisms. Reactive oxygen species are involved in the development and progression of many cancers and has been showed to activate pro-tumorigenic signalling, increase tumour cell survival, proliferation, invasion and metastasis, DNA damage and genetic instability. These are highly reactive and attack various classes of essentials biomolecules such as proteins, DNA and most important lipids. Malondialdehyde is the best investigated product of lipid peroxidation. The aim of this study was to evaluate the prognostic role of malondialdehyde in patients with ovarian adenocarcinoma and in an experimental model.

show abstract

Tumor is an Oxidative Stress Factor in Ovarian Cancer Patients

Cited by 6 publications

References 16 publications

Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods

Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods

Antitumor activity of sitagliptin and vitamin B12 on Ehrlich ascites carcinoma solid tumor in mice

Malondialdehyde as a Prognostic Marker in Patients with Ovarian Adenocarcinoma

Contact Info

Product

Resources

About